Waqas Malick

Waqas Malick

Auto-generated profile, based on publicly available information

Waqas Malick

Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , New York, NY

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2011 in Heart
Verified
Journal Article
Closed access
PDF file
LFLeticia Fernandez-Friera
Leticia Fernandez-Friera
AGAna Garcia-Alvarez
Ana Garcia-Alvarez
GGGabriela Guzmán-Martínez
Gabriela Guzmán-Martínez
FBFatemeh Bagheriannejad-Esfahani
Fatemeh Bagheriannejad-Esfahani
WMWaqas Malick
Waqas Malick
JSJavier Sanz
Javier Sanz
Objective: To evaluate segmental right ventricular (RV) dysfunction in pulmonary hypertension (PH) using cardiac magnetic resonance (CMR). Design: Cross-sectional analysis in a retrospective cohort of consecutive adult patients. Setting: Mount Sinai Hospital in New York. Patients: 192 patients with known or suspected PH undergoing right heart catheterisation and CMR. PH was defined as mean pulmonary artery pressure ≥25 mm Hg. Abnormal RV ejection fraction (RVEF) was defined as <50%. Patients were classified into: group 1 (no PH, normal RVEF; n=40), group 2 (PH, normal RVEF; n=41) or group 3 (PH, abnormal RVEF; n=111). Interventions: CMR and right heart catheterisation within a 2-week interval. Main outcome measures: On cine CMR images, the stack of RV short-axis views was divided into two equal halves. Basal and apical RVEF were calculated using Simpson's method, and a ratio of basal-to-apical RVEF (RVEFratio) was derived. Results: Basal RVEF did not differ between groups 1 and 2 (63±8% vs 64±8%; p=1); however, patients in group 2 had significantly lower apical RVEF (46±13% vs 58±10%; p<0.01) and higher RVEFratio (median 1.4 vs 1.1; p<0.01). Both apical and basal RVEF were reduced in group 3 compared with groups 1 and 2 (p<0.01), and the RVEFratio increased with increasing PH severity (p<0.01 for trend). An apical RVEF <50% was more sensitive than global RV dysfunction for the detection of PH. Conclusions: Apical dysfunction appears to occur before global RVEF decreases in chronic PH, potentially constituting an early and sensitive marker of RV dysfunction in this setting.

5 March 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
WMWaqas A Malick
Waqas A Malick
DCDaein Choi
Daein Choi
ALAnne Langsted
Anne Langsted
VBVera Bittner
Vera Bittner
BNBørge G Nordestgaard
Børge G Nordestgaard
RRRobert S Rosenson
Robert S Rosenson
Low-density lipoprotein cholesterol (LDL-C) is the pre-eminent target for the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). Despite the expansive evidence supporting therapeutic reductions in LDL-C with statin therapy, many high-risk patients do not achieve guideline-recommended treatment targets resulting in avoidable cardiovascular events and higher healthcare expenditures. Underutilization of effective LDL-C lowering is exacerbated by low adherence to statin therapy even among patients following an acute coronary event. Adjunctive therapies such as ezetimibe and PCSK9 monoclonal antibodies remain underutilized, and polypharmacy regimens used for the treatment of cardiovascular disease further increase challenges for patients. Although cardiovascular outcomes data are lacking, inclisiran, a small-interfering RNA (siRNA) targeting PCSK9 mRNA, is available for clinical use. Novel implementation approaches offer the opportunity for more durable or even potentially permanent solutions for lipoprotein-associated cardiovascular disease risk. As an adjunct to statins, these novel approaches may offer more durable approaches for the prevention of ASCVD events. In this review, we discuss the challenges of current LDL-C lowering therapies, achieving LDL-C targets and the necessity of novel approaches.

10 June 2023 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
LCLisandro Colantonio
Lisandro Colantonio
SGSascha N. Goonewardena
Sascha N. Goonewardena
ZWZhixin Wang
Zhixin Wang
EJElizabeth A. Jackson
Elizabeth A. Jackson
MFMichael E. Farkouh
Michael E. Farkouh
RRRobert S. Rosenson
Robert S. Rosenson

28 August 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
LCLisandro Colantonio
Lisandro Colantonio
ZWZhixin Wang
Zhixin Wang
LGLama Ghazi
Lama Ghazi
CAChibuike J Alanaeme
Chibuike J Alanaeme
ACAshley Christenson
Ashley Christenson
VBVera Bittner
Vera Bittner
Aims: Small observational studies suggest that aspirin use may be associated with a 50% lower incidence of cardiovascular disease (CVD) in adults with lipoprotein(a) ≥ 50 mg/dL, without apparent benefit in those with lipoprotein(a) < 50 mg/dL. The current study aimed to replicate prior findings in a large, multicohort study. Methods: We analyzed publicly available data from adults without CVD in the ARIC (baseline 1987-1989), CHS (1989-1993), and MESA (2000-2002) studies. High lipoprotein(a) was defined by a mass concentration of ≥50 mg/dL or equivalent. Follow-up for CVD (myocardial infarction, stroke, or CVD death) and coronary heart disease (CHD; myocardial infarction, or CHD death) was available through 2018 in ARIC, 2011 in CHS, and 2015 in MESA. Mixed-effects models were used to obtain pooled results across studies. Results: Aspirin use in ARIC (n = 13,085), CHS (n = 3,956), and MESA (n = 6,621) was 25.1%, 29.6%, and 19.3%, respectively. Using propensity score matching, the HR (95%CI) for CVD associated with aspirin use among participants with high and low lipoprotein(a) was 1.12 (0.96, 1.31) and 1.04 (0.96, 1.13), respectively (p-value comparing HRs: 0.38). The HR (95%CI) for CHD associated with aspirin use among participants with high and low lipoprotein(a) was 1.01 (0.82, 1.23) and 1.02 (0.92, 1.13), respectively (p-value comparing HRs: 0.94). No evidence of an association of aspirin use with lower CVD risk was present in participants with high or low lipoprotein(a) in subgroup analyses. Conclusion: There was no evidence to suggest that the association between aspirin and the incidence of CVD may differ by lipoprotein(a) levels.